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Abstract
Objective: The amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPAR) is increasingly recognized as a therapeutic target in drug-refractory
pediatric epilepsy. Perampanel (PER) is a non-competitive AMPAR antagonist,
and pre-clinical studies have shown the AMPAR-mediated anticonvulsant
effects of decanoic acid (DEC), a major medium-chain fatty acid provided in
the medium-chain triglyceride ketogenic diet. Methods: Using brain tissue
resected from children with intractable epilepsy, we recorded the effects of PER
and DEC in vitro. Results: We found resected pediatric epilepsy tissue exhibits
spontaneous epileptic activity in vitro, and showed that DEC and PER inhibit
this epileptiform activity in local field potential recordings as well as excitatory
synaptic transmission. Interpretation: This study confirms AMPAR antagonists
inhibit epileptiform discharges in brain tissue resected in a wide range of pedi-
atric epilepsies.
Introduction
Molecular targets for pediatric epilepsy treatment have
largely centered on voltage-gated sodium and calcium
channels. The recent introduction of Perampanel (PER),
a non-competitive amino-3-hydroxy-5-methyl-4-isoxa-
zolepropionic acid receptor (AMPAR) antagonist, has
introduced the concept of AMPAR modulation as an
effective anticonvulsant strategy.1,2 Similarly, recent
studies in epilepsy rodent models have demonstrated
the anti-epileptic action of decanoic acid (DEC), a
major medium-chain fatty acid provided in the med-
ium-chain triglyceride (MCT) ketogenic diet (KD), is
mediated through direct and selective inhibition of
AMPARs.3,4
Human tissue samples provide a valuable tool for pre-
clinical drug screening and mechanism-of-action epilepsy
studies.5 This is particularly useful in pediatrics, where
few anticonvulsant drug trials include children and adult
study results are often extrapolated to children with pedi-
atricians prescribing “off-label”.6 In most human brain
tissue preparations, epileptiform activity is induced
through manipulation of artificial cerebrospinal fluid
(aCSF) magnesium or potassium or by adding pro-con-
vulsant agents (e.g. 4-aminopyridine).7-10 We have found
pediatric human brain tissue to be hyperexcitable and
have recorded spontaneous epileptic activity. We show
that antagonism of AMPAR has a profound anticonvul-
sant effect in tissue derived from a spectrum of difficult-
to-treat seizure syndromes.
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1
Methods
Human tissue collection and slice
preparation
Human tissue was obtained with informed consent from
pediatric patients undergoing epilepsy surgery at Birming-
ham Children’s Hospital. Ethical approval was obtained
from the Black Country Local Ethics Committee (10/
H1202/23; 30 April 2010), and from Aston University’s
ethics committee (Project 308 cellular studies in epilepsy)
and through the Research and Development Department at
Birmingham Children’s Hospital (IRAS ID12287). Speci-
mens were resected intraoperatively with minimal trau-
matic tissue damage, and minimal use of electrocautery.
For transport to the laboratory, samples were transferred
immediately to ice-cold choline-based artificial cere-
brospinal fluid (aCSF) standardized for use in human tissue
experiments8-11 containing in mmol/L: 110 choline chlo-
ride, 26 NaHCO3, 10 D-glucose, 11.6 ascorbic acid, 7
MgCl2, 3.1 sodium pyruvate, 2.5 KCl, 1.25 NaH2PO4, and
0.5 CaCl2 with added 0.04 indomethacin and 0.3 uric acid
for neuroprotection, and bubbled with carbogen (95% O2,
5% CO2). For slice storage and experiments, aCSF contain-
ing (in mmol/L): 125 NaCl, 3 KCl, 1.6 MgSO4, 1.25
NaH2PO4, 26 NaHCO3, 2 CaCl2, 10 Glucose, was used.
Local field potential (LFP) recordings
About 450 µm thick brain slices were prepared and stored
and recordings made as previously reported.12 Epilepti-
form events were classified as activity displaying an ampli-
tude fourfold greater than the root mean square baseline
amplitude, providing the event count, while the time dif-
ference between these events provided the interevent
interval (IEI). Statistical analysis was conducted using
Prism 8. Measurements expressed as median (M),
interquartile range (Q1–Q3) and min–max values.
Whole-cell patch-clamp (WCPC) recordings
Whole-cell recordings were made using standard tech-
niques.13 Electrodes were filled with an internal solution
containing (in mmol/L): 100 CsCl, 40 HEPES, 1 Qx-314,
0.6 EGTA, 5 MgCl2, 10 TEA-Cl, 4 ATP-Na, 0.3 GTP-Na
(titrated with CsOH to pH 7.25) at 290–295 mOsm for
IPSCs. Also included in the electrode was 1–3 mmol/L 1
IEM 1460, which blocks ionotropic glutamate receptors
from inside the cell.13 For EPSCs the internal solution
contained (in mmol/L): 100 Cs-gluconate, 40 HEPES, 1
Qx-314, 0.6 EGTA, 2 NaCl, 5 Mg-gluconate, 5 TEA-Cl,
10 Phospho-Creatinine, 4 ATP-Na, 0.3 GTP-Na (titrated
with CsOH to pH 7.3) at 285 mOsm. The EPSCs and
IPSCs were recorded as apparent inward currents at
70 mV using Axopatch 200B amplifier (Molecular
Devices, San Jose, CA, USA). Signals were low-pass fil-
tered at 5 kHz with an 8-pole Bessel filter and digitized at
10 kHz using a Digidata 1440A and pClamp software
(Molecular Devices). Data were analyzed using Axograph
and Prism 8. Measurements are expressed as mean
median  SEM.
Drugs
DEC (Sigma, Dorset, UK) and PER (Eisai, Hatfield, UK)
were prepared as 1 M stock using dimethyl sulfoxide.
Results
Patient data
Brain tissue was obtained from 16 patients (F:M 9:7),
median age 10.5 years (range 3–18 years). Surgical proce-
dures included temporal resection (seven), hemispherec-
tomy (five), occipital lobectomy (one), and frontal
resection (three). One patient was on the modified KD
pre-surgery (Table 1).
DEC reduces spontaneous epileptiform
activity in paediatric epilepsy tissue in vitro
LFP recordings were assessed for spontaneous epilepti-
form activity (Fig. 1B) before addition of DEC at increas-
ing concentrations (Fig. 1A). DEC significantly reduced
the frequency of epileptiform events per minute com-
pared to control conditions (control [M = 2.46, Q1–
Q3 = 1.47–2.84, min–max = 0.53–3.10; n = 5] vs.
300 µmol/L [M = 0.25, Q1–Q3 = 0.14–0.78, min–
max = 0.13–0.88; n = 5, P < 0.05] and 1 mmol/L con-
centrations [M = 0.25, Q1–Q3 = 0.08–0.45, min–
max = 0.02–0.62; n = 5, P < 0.05]; Friedman test with
Dunn’s post-test; Fig. 1C). The IEI of epileptic activity
increased significantly with all concentrations of DEC
(Control [M = 3.18 sec, Q1–Q3 = 0.75–7.33 sec; n = 5]
vs. 100 µmol/L [M = 6.76 sec, Q1–Q3 = 2.87–16.40 sec;
n = 5, P < 0.005], 300 µmol/L [M = 12.12 sec, Q1–
Q3 = 5.44–26.01 sec; n = 5, P < 0.005] and 1 mmol/L
[M = 26.11 sec, Q1–Q3 = 8.29–51.27 sec; n = 5,
P < 0.005]; Kruskal–Wallis with Dunn’s post-test;
Fig. 1D).
DEC inhibits excitatory but not inhibitory
postsynaptic currents
The effects of DEC on synaptic activity were investigated
using the WCPC technique to assess spontaneous
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excitatory and inhibitory postsynaptic currents (sEPSCs/
sIPSCs; Fig. 1E–M). As Figure 1F shows, application of
1 mmol/L DEC significantly increased the IEI (248  145
vs. 752  175 msec, n = 6 cells, P = 0.03) with no
change in the amplitude of sEPSCs (19.8  1.9 vs.
17.4  1.2 pA, n = 6, P = 0.1), or charge transfer
(Fig. 1G; 641  265 vs. 350  114 fC, n = 6, P = 0.5).
We next tested the location of the DEC effects by testing
the effect of DEC in the presence of tetrodotoxin (TTX,
1 µmol/L). As Figure 1H shows, after addition of TTX
there was a significant reduction of amplitude
(20.9  1.9 vs. 18.2  0.8 pA, n = 6 cells, P = 0.03), but
no significant change in the IEI of mEPSCs (Fig. 1I;
627  172 vs. 656.5  211 msec, n = 6 cells, P = ns) or
charge transfer (Fig. 1J; 192  127 vs. 195  60 fC,
n = 6, P = 0.5) with 1 mmol/L DEC, suggesting DEC
may act on postsynaptic AMPARs.
Since inhibitory interneurons are subject to glutamater-
gic drive, any change in AMPAR activity is likely to
depress gamma-aminobutyric acid (GABA) release and,
indeed, we have seen this in recordings where PER is
applied. It seems unlikely, however, that DEC would have
any direct effect on GABA release. To investigate the
actions of DEC on isolated inhibitory synaptic currents,
we used whole-cell patch electrodes filled with the iono-
tropic glutamate receptor channel blocker, IEM-1460, at
1.5 mmol/L. Under these conditions, in which AMPARs
were blocked from inside the recorded cell, we recorded
miniature IPSCs (mIPSCs) from principal neurons in the
presence of TTX 1 µmol/L (Fig. 1K). Analysis of pooled
data revealed no significant change in amplitude,
(28.9  2.5 vs. 30.1  2.2 pA, n = 5, P = ns), IEI of
recorded mIPSCS after addition of 1 mmol/L DEC
(Fig. 1L; 129.3  10.9 vs. 96.6  14.3 msec, n = 5,
P = ns), or charge transfer (Fig. 1M; 4912  728 vs.
5751  2503 fQ, n = 5, P = ns).
PER abolishes spontaneous epileptiform
activity in pediatric epilepsy tissue in vitro
LFP recordings were assessed for spontaneous epilepti-
form activity (Fig. 2B) before addition of PER (Fig. 2A).
PER significantly reduced the number of epileptiform
events per minute compared to control conditions (con-
trol [M = 1.48, Q1–Q3 = 0.63–2.20, min–max = 0.47–
4.33; n = 7] vs. PER 10 µmol/L [M = 0.35, Q1–
Q3 = 0.13–0.83, min–max = 0.05–0.87]; n = 7, P < 0.05;
Wilcoxon test Fig. 2C). Application of PER also increased
the IEI (Fig. 2D; control [M = 2.89 sec, Q1–Q3 = 0.89–
7.51 sec; n = 7] vs. 10 µmol/L PER [M = 12.01 sec, Q1–
Q3 = 3.50–27.48 sec; n = 7], P < 0.005).
PER inhibits excitatory but not inhibitory
postsynaptic currents
To gain a better understanding of PER’s ability to abolish
spontaneous epileptiform activity, recordings of neuro-
transmitter release were conducted (Fig. 2E–J). Record-
ings revealed that principal neurons received GABAergic
IPSCs with a mean median IEI of 96.99  23.23 msec
(Fig. 2F) and a mean median amplitude of
Table 1. Patient data.
Patient Operation Medication Histology
1 Right frontal
disconnection
and resection
Modified KD
Sodium
valproate
Vigabatrin
No definite
abnormal
pathology
2 Left temporal
lobectomy
Topiramate
Carbamazepine
Gliosis
3 Right temporal
lobectomy
Lamotrigine Gliosis, in keeping
with secondary
changes associated
with epilepsy
4 Hemispherotomy Clonazepam
Carbamazepine
Levetiracetam
Gliosis
5 Left temporal
lobectomy and
hippocampectomy
Clobazam
Levetiracetam
Lamotrigine
Hippocampal
sclerosis
6 Left temporal
lobectomy
Lamotrigine Hippocampal
sclerosis
7 Hemispherotomy Oxcarbazepine
Levetiracetam
Gliosis, in keeping
with secondary
changes associated
with epilepsy
8 Left temporal
lobectomy
Topiramate
Carbamazepine
Low grade
glioneuronal
neoplasm
9 Left temporal
lobectomy
Carbamazepine Hippocampal
sclerosis
10 Occipital
lobectomy
Lamotrigine
Sodium
valproate
Cortical damage
11 Frontal resection Topiramate
Clobazam
Focal cortical
dysplasia Type IIB
12 Frontal resection Carbamazepine
Brivacetam
Focal cortical
dysplasia Type IA
13 Temporal
lobectomy
Levetiracetam
Carbamezapine
Mesial temporal
sclerosis
14 Hemispherotomy Topiramate
Carbamazepine
Clobazam
Focal cortical
dysplasia
15 Hemispherotomy Lamotrigine
Carbamezapine
Rasmussens
encephalitis
16 Hemispherotomy Levetiracetam
Caarbamezapine
Polymicrogyria
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36.28  8.33 pA. In the presence of PER (10 µmol/L)
there was no significant change in IEI (Fig. 2F;
88.93  16.55 msec, n = 6, P = ns), amplitude
(25.19  3.82 pA, P > 0.05) or charge transfer (Fig. 2G;
16.46  10.91 vs. 10.16  0.54 pC, n = 6, P = 0.1).
When we recorded sEPSCs (Fig. 2H), IEI was significantly
increased from 173  217 to 2361  873 msec
(P = 0.03) in the presence of PER (Fig. 2I). The effect of
PER on amplitude did not reach statistical significance
(19.87  4.1 to 10.83  2.92 pA; P = 0.06), but the
charge transfer was significantly reduced (Fig. 2J;
341  1622 vs. 169  115 fC, n = 6, P = 0.03).
Discussion
This study confirms that AMPAR inhibition, either by
DEC or PER, is effective in abolishing spontaneous
epileptiform activity in human tissue from drug-resistant
pediatric epilepsy patients through a direct reduction in
excitatory neurotransmission.
DEC, a major constituent of the MCT KD, has previ-
ously been shown to have an anticonvulsant action in
acute in vitro rat hippocampal slice models of epilepti-
form activity, acting through modulation of excitatory
neurotransmission.3-5 In our human tissue LFP record-
ings, the anticonvulsant effects of DEC were clearly
demonstrated at the 300 µmol/L concentration, consistent
with reported therapeutic pediatric plasma concentra-
tions.14,15 In WCPC experiments, the anticonvulsant
mechanism was shown to be likely through the reduction
of post-synaptic excitatory neurotransmission via
AMPARs.
Similar effects were seen with PER, via a reduction in
the frequency of EPSCs and overall charge transfer. These
effects were observed in tissue from a wide array of epi-
lepsy syndromes, and underline the importance of the
AMPAR in understanding the development and treatment
of the epilepsies. Like many aspects of epilepsy, it is not a
simple case of ‘too much’ AMPAR activity leading to sei-
zures, for example, in anti-AMPAR autoimmune
encephalitis, antibodies generated against AMPAR epi-
topes lead to AMPAR internalization, thereby reducing
excitatory drive while still causing temporal lobe seizures
in man.16,17 Similarly, recent work in a rat model of
chronic TLE in our laboratory suggests that seizures
induce a profound loss of AMPAR expression in vulnera-
ble networks.12 Hence, AMPARs would appear to play
both causative and compensatory roles in seizures and
epileptogenesis.
Currently, the management for children with drug-re-
sistant epilepsy includes referral to an epilepsy surgery
unit for assessment of suitability for resective surgery.
Researchers have attempted to explore the role of the KD
in improving seizure outcomes in epilepsy surgery
patients with Focal Cortical Dysplasia Type II (the
EDIBLE research study: www.edible.org.uk). While studies
in human brain tissue do not provide a substitute for
clinical trials in children, this preclinical study suggests
that the MCT KD or PER may be effective in reducing
seizure burden pre-operatively for these patients. Indeed,
a synergistic therapeutic effect of DEC and PER was
recently demonstrated in a study using in vitro epilepsy
animal models and adult human tissue from brain tumor
patients.4
One criticism of human epileptic tissue research is the
lack of “control” tissue.18,19 For obvious ethical reasons,
we cannot and will never have the opportunity to obtain
pediatric “normal” brain tissue for the ideal control.
However, this should not prevent the use of human tissue
as an invaluable resource to study the true pathophysio-
logical changes in pediatric drug-resistant epilepsy. Recent
studies in human brain tissue have demonstrated the
presence of extensive species-specific differences in neuron
types and properties as compared to the rodent brain.20,21
A clear example of this is the expression of 5HT3 recep-
tors, which are present on excitatory cells throughout the
human forebrain, but expressed only on inhibitory GABA
cells in rodent brain.22 Therefore, the use of human
epileptic brain tissue could provide novel insights to com-
plement preclinical animal model studies. This is of the
particular importance of the testing of treatments in med-
ically refractory epilepsy, as few animal models recapitu-
late fully the diversity of seizure types, localization and
etiology of the patients seen in the clinic. In pediatric
Figure 1. Decanoic acid reduces spontaneous epileptiform activity in pediatric epilepsy tissue samples. (A) Example trace of local field potential
recording before and after consecutive addition of DEC. Scale bar 100 µV versus 60 sec. (B) Two examples of spontaneous epileptiform activity
from separate pediatric human tissue recordings. Black bar denotes zoomed in section of events. Scale bars (top) 40 µV versus 500 msec,
(bottom) 100 µV versus 2 sec. (C) Pooled events per minute under various conditions. (D) The interevent interval in different concentrations of
DEC. (E) Example trace of sEPSCs from pediatric human tissue before (top) and after (bottom) treatment with 1 mmol/L DEC. Scale bar 50 pA
versus 1 sec. (F) Pooled mean-median inter-event interval in 1 mmol/L DEC. (G) Pooled sEPSC charge transfer in 1 mmol/L DEC. (H) Pooled mean-
medium amplitude of sEPSCs in 1 mmol/L DEC. (I) Pooled inter-event interval of mEPSCs with 1 mmol/L DEC. (J) Pooled charge transfer of
mEPSCs in 1 mmol/L DEC. (K) Example traces of mIPSC recordings pre and post addition of 1 mmol/L DEC. Scale bar 50 pA versus 1 sec. (L)
Pooled interevent interval of mIPSCs in control and 1 mmol/L DEC. (M) Pooled charge transfer of mIPSCS after addition of 1 mmol/L DEC. DEC,
decanoic acid. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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epilepsy research, slice preparations from resected tissue
are extremely valuable and rare, and provide a unique
substrate for testing novel and approved compounds in
pharmacoresistant epilepsy.
In summary, this study shows the potential application
of human tissue samples for epilepsy research and drug
development. The heterogeneity of the human tissue sam-
ples is a true reflection of the variable etiology of refrac-
tory epilepsy and should be considered a strength of the
human tissue approach to pediatric epilepsy research.
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